How Should FDA Collect The Biosimilar Product Development Fee?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA looking at different ways and development milestones to charge the pre-marketing application fee.
You may also be interested in...
Biosimilar User Fee Program Stresses FDA/Sponsor Meetings Early And Often
BsUFA agreement negotiated between the agency and industry provides five different types of meetings during the pre-IND and product development stage. FDA will issue a draft guidance on the different types of biosimilar meeting opportunities by 2014.
FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials
European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.
FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials
European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.